Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Transplant Cell Ther. 2021 Feb 4;27(5):389.e1–389.e10. doi: 10.1016/j.jtct.2021.02.002

Figure 1. Ruxolitinib inhibits IFN γ mediated expression of IDO protein via JAK-STAT1 pathway.

Figure 1.

MSCs were treated with IFNγ (20ng/mL) and/or Ruxolitinib (at concentrations shown) (A) Cells were collected post 48 hrs. of treatment to perform western blot. Cells were probed with antibodies against pSTAT1, total STAT1 and IDO. Beta Actin was used as a loading control. (B) Cells were treated with IFNγ (20ng/mL) with two representative concentrations of Ruxolitinib (10nM and 10 μM). Lysates were collected at various time points to determine the ruxolitinib’s kinetics on JAK/STAT inhibition. Similar results were obtained in a repeat experiment.